This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Sponsored by Omeros Corporation

About this trial

Last updated 8 years ago

Study ID

OMS302-ILR-004

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

Yes

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 12 years ago

What is this trial about?

The purpose of this study is to determine the safety, efficacy and pharmacokinetics of OMS302 (the study drug) for maintaining intraoperative mydriasis and preventing post operative pain in individuals undergoing Intraocular Lens Replacement (ILR) surgery.

What are the participation requirements?

Yes

Inclusion Criteria

- Competent and willing to voluntarily provide informed consent

- 18 years of age or older

- In good general health needing to undergo cataract extraction or lens extraction with lens replacement surgery in one eye, under topical anesthesia

No

Exclusion Criteria

- No allergies to the medications and/or the active ingredients of any of the study medications

- No medications with the same activities of the active ingredients in OMS302 for defined time intervals prior to and after surgery

- No other significant eye injuries, eye conditions or general medical conditions likely to interfere with the evaluation of the study medication

Locations

Location

Status